REGENXBIO Achieves Key Milestones in Duchenne and Retinal Gene Therapy Studies, Maintaining Strong Cash Position Into 2027
RGX-202 Delivers Statistically Significant Results in Duchenne Trial
REGENXBIO's pivotal Phase III AFFINITY DUCHENNE study for its lead gene therapy, RGX-202, has reached a crucial milestone. The study demonstrated a highly statistically significant achievement on its primary endpoint, with 93% of patients exceeding 10% microdystrophin expression at week 12 (p<0.0001). Interim safety results confirm the therapy was well-tolerated, supporting continuing confidence in its profile.
Additionally, the trial revealed a significant correlation between RGX-202 microdystrophin levels and patient functional improvement (NSAA scores; n=9 at 12 months), strengthening the clinical case for this gene therapy as a potential best-in-class option for Duchenne muscular dystrophy. All 60 patients in pivotal and confirmatory trials are expected to complete dosing by mid-year, supporting a pathway to potential accelerated approval in 2027.
| RGX-202 Trial Metrics | Data Point |
|---|---|
| Primary Endpoint Achieved | Yes (p<0.0001) |
| Microdystrophin Expression Above 10% | 93% of Patients |
| Interim Functional Data (NSAA, n=9 at 12mo) | Statistically Significant Correlation |
| Interim Safety Profile | Well-tolerated |
Milestone Payments and Major Data Releases in Retinal Programs
REGENXBIO is strengthening its collaboration with AbbVie on surabgene lomparvovec (ABBV-RGX-314), a potential first-in-class gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Topline results from the pivotal ATMOSPHERE and ASCENT trials (subretinal delivery for wet AMD) are on track for Q4 2026, with U.S. clinical sites active for the pivotal NAAVIGATE study in diabetic retinopathy. Upon dosing the first patient in this trial’s Phase IIb portion, REGENXBIO will receive a $100 million milestone payment from AbbVie, expected this quarter.
Regulatory Progress for Hunter Syndrome Therapy and Expanded Pipeline
The partial clinical hold on RGX-121 for Mucopolysaccharidosis (MPS) II (Hunter syndrome) has been lifted, and ongoing discussions with the FDA continue regarding program milestones. The company is also progressing in its rare disease pipeline, with partnerships extending its gene therapy reach into additional indications.
Financial Resilience Supports Ongoing Pipeline Development
Despite reporting a net loss of $90.05 million for Q1 2026, REGENXBIO maintains a robust balance sheet. As of March 31, 2026, the company held $150.5 million in cash, cash equivalents, and marketable securities—sufficient to fund operations into early 2027, excluding potential milestone payments and additional financings.
| Financial Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Cash, Cash Equivalents & Marketable Securities | $150.5M | $240.9M |
| Revenues | $6.39M | $89.01M |
| R&D Expenses | $57.34M | $53.09M |
| Net Income (Loss) | ($90.05M) | $6.08M |
The revenue shortfall was primarily due to the expiration of certain ZOLGENSMA patent royalties and a high licensing revenue recognized in Q1 2025. Operational spending, driven by clinical progress—including a non-recurring $10 million settlement—remained in line with expectations.
Key Catalysts Ahead: Multiple Readouts and Regulatory Milestones
Several high-value milestones are expected for REGENXBIO in the coming quarters, including pivotal data releases for RGX-202 and ABBV-RGX-314, the first patient dosing in key retinal trials, and potential accelerated regulatory paths for major pipeline agents. Investors and stakeholders may want to monitor these program advances and upcoming partnership payments, which could further extend the company's cash runway and accelerate the timeline to potential market approvals.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI